California State Teachers Retirement System raised its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 24.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 31,500 shares of the company’s stock after buying an additional 6,200 shares during the quarter. California State Teachers Retirement System’s holdings in Kura Oncology were worth $471,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Rhumbline Advisers purchased a new stake in shares of Kura Oncology in the 2nd quarter valued at about $131,000. New York State Common Retirement Fund purchased a new stake in shares of Kura Oncology in the 2nd quarter valued at about $142,000. OxFORD Asset Management LLP purchased a new stake in shares of Kura Oncology in the 2nd quarter valued at about $217,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Kura Oncology in the 2nd quarter valued at about $226,000. Finally, Nationwide Fund Advisors lifted its holdings in shares of Kura Oncology by 66.2% in the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after purchasing an additional 10,258 shares during the last quarter. 62.96% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently weighed in on KURA. BidaskClub raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Wedbush began coverage on Kura Oncology in a report on Tuesday, December 26th. They issued a “buy” rating and a $19.00 target price for the company. Oppenheimer set a $18.00 target price on Kura Oncology and gave the company a “buy” rating in a report on Thursday, November 16th. ValuEngine downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.08.

Shares of Kura Oncology, Inc. (KURA) opened at $18.80 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48. The company has a market capitalization of $598.27, a P/E ratio of -12.13 and a beta of 4.94. Kura Oncology, Inc. has a one year low of $5.90 and a one year high of $21.00.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). equities research analysts predict that Kura Oncology, Inc. will post -1.52 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “California State Teachers Retirement System Has $471,000 Stake in Kura Oncology, Inc. (KURA)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/california-state-teachers-retirement-system-has-471000-stake-in-kura-oncology-inc-kura/1847541.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.